The efficacy and safety of darbepoetin alfa for treating anemia in low-risk myelodysplastic syndrome patients: Results after 53/55 weeks.

被引：0
|
作者：
Gabrilove, Janice
Paquette, Ronald
Lyons, Roger M.
Mushtaq, Chaudhry
Sekeres, Mikkael A.
Lam, Hung
Dreiling, Lyndah
机构：
[1] Mt Sinai Sch Med, Dept Med, New York, NY USA
[2] Univ Calif Los Angeles, Ctr Oncol, Los Angeles, CA USA
[3] Canc Care Ctr S Texas, US Oncol Res, San Antonio, TX USA
[4] S Carolina Oncol Associates, Columbia, SC USA
[5] Taussig Canc Ctr, Cleveland Clin, Cleveland, OH 44106 USA
[6] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.2671.2671
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2671
引用
收藏
页码：755A / 755A
页数：1
相关论文
共 50 条
  • [1] Darbepoetin alfa for treating anemia in low-risk myelodysplastic syndrome patients: Interim results after 27/28 weeks.
    Paguette, R.
    Gabrilove, J.
    Lyons, R.
    Mushtaq, C.
    Sekeres, M.
    Lam, H.
    Dreiling, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 352S - 352S
  • [2] Darbepoetin alfa for treating anemia in patients with low-risk myelodysplastic syndromes: Exploratory analysis of baseline predictors of response.
    Gabrilove, J.
    Paquette, R.
    Lyons, R.
    Mushtaq, C.
    Sekeres, M.
    Lam, H.
    Dreiling, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 356S - 356S
  • [3] Examining the safety and efficacy of imetelstat in low-risk myelodysplastic syndrome
    Thomas, Xavier
    EXPERT OPINION ON PHARMACOTHERAPY, 2025, 26 (05) : 525 - 533
  • [4] The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study
    Ak, Muzeyyen Aslaner
    Sahip, Birsen
    Geduk, Ayfer
    Ucar, Mehmer Ali
    Kale, Hacer
    Hacibekiroglu, Tugba
    Polat, Merve Gokcen
    Kalpakci, Yasin
    Bolaman, Ali Zahit
    Guvenc, Birol
    Ertop, Sehmus
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2022, 38 (02) : 299 - 308
  • [5] The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study
    Muzeyyen Aslaner Ak
    Birsen Sahip
    Ayfer Geduk
    Mehmer Ali Ucar
    Hacer Kale
    Tugba Hacibekiroglu
    Merve Gokcen Polat
    Yasin Kalpakci
    Ali Zahit Bolaman
    Birol Guvenc
    Sehmus Ertop
    Indian Journal of Hematology and Blood Transfusion, 2022, 38 : 299 - 308
  • [6] Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome
    Spiriti, MAA
    Latagliata, R
    Niscola, P
    Cortelezzi, A
    Francesconi, M
    Ferrari, D
    Volpe, E
    Clavio, M
    Grossi, A
    Reyes, MT
    Musto, P
    Mitra, ME
    Azzarà, A
    Pagnini, D
    D'Arena, G
    Spadano, A
    Balleari, E
    Pecorari, P
    Capochiani, E
    De Biasi, E
    Perego, D
    Monarca, B
    Pisani, F
    Scaramella, G
    Petti, MC
    ANNALS OF HEMATOLOGY, 2005, 84 (03) : 167 - 176
  • [7] Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome
    M. A. Aloe Spiriti
    R. Latagliata
    P. Niscola
    A. Cortelezzi
    M. Francesconi
    D. Ferrari
    E. Volpe
    M. Clavio
    A. Grossi
    M. Tambone Reyes
    P. Musto
    M. E. Mitra
    A. Azzarà
    D. Pagnini
    G. D’Arena
    A. Spadano
    E. Balleari
    P. Pecorari
    E. Capochiani
    E. De Biasi
    D. Perego
    B. Monarca
    F. Pisani
    G. Scaramella
    M. C. Petti
    Annals of Hematology, 2005, 84 : 167 - 176
  • [8] Phase II trial of darbepoetin alfa in myelodysplastic syndrome (MDS):: Preliminary efficacy, safety, and in vitro results.
    Gotlib, J
    Quesada, S
    Bhamidipati, J
    Chaudry, K
    Sridhar, K
    Dugan, K
    Stein, R
    Tupper, G
    Greenberg, PL
    BLOOD, 2004, 104 (11) : 267B - 268B
  • [9] A phase 2, single-arm, open-label trial to evaluate the effectiveness of darbepoetin alfa for the treatment of anemia in patients with low-risk myelodysplastic syndrome.
    Gabrilove, J
    Paquette, R
    Lyons, R
    Mushtaq, C
    Sekeres, M
    Lam, H
    Dreiling, L
    BLOOD, 2005, 106 (11) : 714A - 714A
  • [10] Treatment of Anemia with Darbepoetin Alfa in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndromes. Results from the ARAMYS Study
    Villegas, Ana
    Arrizabalaga, B.
    Fernandez-lago, C.
    Mouzo, M.
    Mayans, Jr
    Gonalez-Porras, Jr
    Duarte, Rafael
    Remacha, Angel Francisco
    Luno, Elisa
    Gasquet, J. A.
    BLOOD, 2008, 112 (11) : 1184 - 1184
12345